Use of clinical next-generation sequencing to identify melanomas harboringSMARCB1mutations

Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups

(2015) Michele Simbolo et al.   Oncotarget

SMARCB1 (INI1)-negative Rhabdoid Carcinomas of the Gastrointestinal Tract

(2014) Abbas Agaimy et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Finding the Right Balance of BRAF Inhibition in Melanoma

(2014) M. A. Davies   Cancer Discovery

Emerging insights into resistance to BRAF inhibitors in melanoma

(2013) Amanda D. Bucheit et al.   BIOCHEMICAL PHARMACOLOGY

BRAF in Melanoma: Current Strategies and Future Directions

(2013) A. K. S. Salama et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancer--Mechanisms and Potential Therapeutic Insights

(2013) X. Wang et al.   CLINICAL CANCER RESEARCH

Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes

(2013) Rajesh R. Singh et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Cutaneous melanoma

(2013) Alexander MM Eggermont et al.   LANCET

SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ

(2013) M. Brenca et al.   MOLECULAR CANCER THERAPEUTICS

Emerging patterns of somatic mutations in cancer

(2013) Ian R. Watson et al.   NATURE REVIEWS GENETICS

Targeted therapy for melanoma: rational combinatorial approaches

(2013) L N Kwong et al.   ONCOGENE

BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene

(2013) Srinivas V. Saladi et al.   Pigment Cell & Melanoma Research

The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers

(2013) A. Hunter Shain et al.   PLoS One

SMARCB1 Deficiency in Tumors From the Peripheral Nervous System

(2012) Daniela Rizzo et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

High-resolution genomic analysis suggests the absence of recurrent genomic alterations other thanSMARCB1aberrations in atypical teratoid/rhabdoid tumors

(2012) Martin Hasselblatt et al.   GENES CHROMOSOMES & CANCER

A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers

(2012) Ryan S. Lee et al.   JOURNAL OF CLINICAL INVESTIGATION

Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions

(2012) Lisa M Sullivan et al.   MODERN PATHOLOGY

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

(2012) Michael Krauthammer et al.   NATURE GENETICS

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reviewing the somatic genetics of melanoma: from current to future analytical approaches

(2012) Ken Dutton-Regester et al.   Pigment Cell & Melanoma Research

Atypical Teratoid/Rhabdoid Tumor Arising in a Ganglioglioma

(2011) B.K. Kleinschmidt-DeMasters et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Epithelioid Malignant Peripheral Nerve Sheath Tumor Arising in a Schwannoma, in a Patient With “Neuroblastoma-like” Schwannomatosis and a Novel Germline SMARCB1 Mutation

(2011) Jodi M. Carter et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri

(2011) Pepijn van den Munckhof et al.   NEUROGENETICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic determinants in epithelioid sarcoma

(2010) Patrizia Gasparini et al.   EUROPEAN JOURNAL OF CANCER

Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas

(2010) I. Christiaans et al.   JOURNAL OF MEDICAL GENETICS

ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas

(2010) Kimberly C. Wiegand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors

(2010) Katherine W. Eaton et al.   PEDIATRIC BLOOD & CANCER

SMARCB1/INI1 Protein Expression in Round Cell Soft Tissue Sarcomas Associated With Chromosomal Translocations Involving EWS: A Special Reference to SMARCB1/INI1 Negative Variant Extraskeletal Myxoid Chondrosarcoma

(2009) Kenichi Kohashi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Rapid detection of SMARCB1 sequence variation using high resolution melting

(2009) Vinod Dagar et al.   BMC CANCER

Loss of SNF5 Expression Correlates with Poor Patient Survival in Melanoma

(2009) H. Lin et al.   CLINICAL CANCER RESEARCH

Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid Tumors

(2009) E. M. Jackson et al.   CLINICAL CANCER RESEARCH

SMARCB1/INI1maternal germ line mosaicism in schwannomatosis

(2009) TJM Hulsebos et al.   CLINICAL GENETICS

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

SWI/SNF Deficiency Results in Aberrant Chromatin Organization, Mitotic Failure, and Diminished Proliferative Capacity

(2009) Ryan J. Bourgo et al.   MOLECULAR BIOLOGY OF THE CELL

The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a

(2009) Therese M Becker et al.   Molecular Cancer

Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation inSnf5+/−;p53+/−mice

(2009) Jessica DelBove et al.   MOLECULAR CARCINOGENESIS